B-cell Tailored Dosing Versus Standard Interval Dosing of Ocrelizumab in Relapsing-Onset MS -Interim Analysis of a Randomized Controlled Trial (BLOOMS Trial)
MULTIPLE SCLEROSIS JOURNAL(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined